Australia Biologics Festival Presentation
Released
Released
Announcement PDF
ASX Announcement/Press Release | 20 February 2024
AdAlta Limited (ASX:1AD)
Australia Biologics Festival Presentation
AdAlta Limited (ASX:1AD) (“AdAlta” or “the Company”) is pleased to announce its participation in the
Australia Biologics Festival to be held between 20 February and 21 February 2024 in Melbourne.
AdAlta CEO and Managing Director, Tim Oldham will be participating in two sessions:
•
On 20 February 2024 at 9:00am AEDT in a leadership panel discussion titled “Current and future state of
the Australian biologics market”.
•
On 21 February 2024 at 10:00am AEDT as an invited presenter on the topic of “Dose estimation and
optimisation for a first in class antifibrotic” which will review the methods and rationale used for dose
selection for Phase II studies of AD-214.
A copy of the presentation is attached.
The Australia Biologics Festival 2024 supports advancing biologics R&D, manufacturing, technology and
innovation in Australian and New Zealand. More information and registration details can be found here:
https://imapac.com/events/australia-biologics-festival/
For further information, please contact:
AdAlta Limited (ASX:1AD)
Tim Oldham
CEO & Managing Director
P: +61 3 9479 5159
E: t.oldham@adalta.com.au
AdAlta Limited (ASX:1AD)
15/2 Park Drive, Bundoora 3083 Victoria Australia
ABN: 92 120 332 925
www.adalta.com.au
Media & Investor Enquiries
The Capital Network
Russell Katz
P: +61 2 8999 3699
E: russell@thecapitalnetwork.com.au
1
About AdAlta Limited
AdAlta Limited is a clinical stage drug development company headquartered in Melbourne, Australia. The
Company is using its proprietary i-body technology platform to solve challenging drug targeting problems and
generate a promising new class of single domain antibody enabled protein and cell therapeutics with the potential
to treat some of today’s most challenging medical conditions.
The i-body technology mimics the shape and stability of a unique and versatile antigen binding domain that was
discovered initially in sharks and then developed as a human protein. The result is a range of unique proteins
capable of interacting with high selectivity, specificity and affinity with previously difficult to access targets such as
G-protein coupled receptors (GPCRs) that are implicated in many serious diseases. i-bodies are the first fully
human single domain antibody scaffold and the first based on the shark motif to reach clinical trials.
AdAlta is extending Phase I clinical studies for its lead i-body® enabled candidate, AD-214, that is being
developed for the treatment of Idiopathic Pulmonary Fibrosis (IPF) and other human fibrotic diseases for which
current therapies are sub-optimal and there is a high unmet medical need. Preparation for Phase II clinical studies
is also underway. AdAlta has a second target in discovery research, also in the field of fibrosis and inflammation.
The Company is also entering collaborative partnerships to advance the development of its i-body® platform. It
has a collaboration with Carina Biotech to codevelop precision engineered, i-body® enabled CAR-T cell therapies
(i-CAR-T) to bring new hope to patients with cancer. It has an agreement with GE Healthcare to co-develop
i-bodies as diagnostic imaging agents (i-PET imaging) against Granzyme B, a biomarker of response to immunooncology drugs, a program now in preclinical development.
AdAlta’s strategy is to maximise the products developed using its next generation i-body® platform by internally
discovering and developing selected i-body enabled product candidates against GPCRs implicated in fibrosis,
inflammation and cancer and partnering with other biopharmaceutical companies to develop product candidates
against other classes of receptor, in other indications, and in other product formats.
For more information
Follow us on Twitter
Follow us on LinkedIn
To learn more about AdAlta please visit: www.adalta.com.au
This ASX announcement has been authorised by the Board of AdAlta Limited (ASX:1AD
2
Dose estimation and
optimization for a first-in-class
anti-fibrotic therapeutic
Tim Oldham PhD
CEO and Managing Director
AdAlta Limited (ASX:1AD)
Australian Biologics Festival
20-21 February 2024
1
Disclaimer
Investment in AdAlta is subject to investment risk, including possible loss of income and capital invested. AdAlta does not
guarantee any particular rate of return or performance, nor do they guarantee the repayment of capital.
This presentation is not an offer or invitation for subscription or purchase of or a recommendation of securities. It does not
take into account the investment objectives, financial situation and particular needs of the investor. Before making any
investment in AdAlta, the investor or prospective investor should consider whether such an investment is appropriate to
their particular investment needs, objectives and financial circumstances and consult an investment advisor if necessary.
This presentation may contain forward-looking statements regarding the potential of the Company’s projects and interests
and the development and therapeutic potential of the company’s research and development. Any statement describing a
goal, expectation, intention or belief of the company is a forward-looking statement and should be considered an at-risk
statement. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of
discovering, developing and commercialising drugs that are safe and effective for use as human therapeutics and the
financing of such activities.
There is no guarantee that the Company’s research and development projects and interests (where applicable) will receive
regulatory approvals or prove to be commercially successful in the future. Actual results of further research could differ
from those projected or detailed in this presentation. As a result, you are cautioned not to rely on forward-looking
statements. Consideration should be given to these and other risks concerning research and development programs
referred to in this presentation.
2
Summary
§ AdAlta’s i-body® platform: a powerful drug discovery tool for targets such as G-protein coupled receptors
(GPCRs) where traditional antibody drugs struggle
§ AdAlta’s AD-214 targets the GPCR CXCR4 and has been specifically designed for the high unmet need in
fibrotic diseases such as Idiopathic Pulmonary Fibrosis (IPF)
§ AD-214’s potential efficacy has been demonstrated using in vitro, ex vivo and animal models of fibrosis
§ AD-214 shows extended CXCR4 receptor occupancy in toxicology and Phase I studies
§ Dose finding is challenging in the absence of reliable biomarkers and limited CXCR4 expression in healthy
volunteers
§ AdAlta has recently used ex vivo models and PK/PD simulations to establish Phase II IV dosing at
clinically convenient two weekly dosing schedules … and to demonstrate the feasibility of an
enhanced weekly SC formulation to enhance patient convenience
3
AdAlta (ASX:1AD) at a glance
AdAlta’s i-body® platform is enabling a high-value product pipeline in two therapeutic areas of
significant unmet medical need
i-body® discovery platform
enables development of
multiple, high value assets
A wholly owned fibrosis and
inflammation pipeline
A co-developed immunooncology pipeline
4
Invention of i-bodies
i-bodies mimic shark VNARs using a human NCAM domain 1 scaffold and randomized synthetic shark VNAR-like
binding loops
CDR3
CDR3
CDR1
CDR1
Ribbon overlay*
Shark VNAR
Basic research on unique
shark immune system …
… led to discovery that the i-set
family of human proteins have
the same scaffold structure …
* Shark VNAR (red); human i-set immunoglobulins (yellow and blue)
hNCAM Domain 1
… leading to the choice of
human NCAM domain 1 for
the current scaffold …
i-body® library
… and invention and patenting of
i-bodies by adding randomized
synthetic VNAR-like binding
loops to NCAM-1
5
An immensely powerful drug discovery platform applicable to multiple
therapeutic formats
Current
examples
Direct therapeutics
For challenging targets,
such as GPCRs
Future
examples
AD-214
Manufacturing and delivery
Targeting agents
Bi-specifics and
multi-specifics
That deliver therapeutic
cargos more precisely
i-PET
i-bodies
To improve targeting
and selectivity
i-CAR-T
• Delivery and expression ex vivo and in
vivo using viral vectors or DNA/RNA
• Efficient i-body® expression in bacterial
fermentation systems
• Mammalian fermentation systems for
more complex formats eg i-body-Fcfusions
• Post synthesis chemical conjugation
i-mRNA
Vectorised antibodies
Small payload for in
situ delivery
i-AAV
6
AdAlta’s pipeline so far: Five active assets plus growing i-body® inventory
Discovery
Target
Product
Indication
Discovery
AD-214
i-body® inventory
Product development
CXCR4
Lung, kidney
fibrosis
Eye fibrosis
Non-clinical
Lead
optimisation
Clinical
Partner
Preclinical
IND enabling
Phase I
IV
SC
IVT
Phase II
Available
to license
Available
to license
TBC
Oncology
GZMB
GZMB-iPET
Cancer imaging
Target A
A-i-CAR-T
Oncology
Target B
B-i-CAR-T
Oncology
Target C
C-i-CAR-T
Oncology
AMA1
TBC
Malaria
Available to co-dev (not
currently active)
GPCR
Target X
TBC
Fibrosis
Available to co-dev (not
currently active)
RANKL
ADR3
Osteoporosis
Available to license (active
academic collaboration)
~25 other
targets
i-body
platform
Platform licenses available
7
Bill van Nierop: IPF survivor on the challenge of living with IPF
“… sadly I am one of a few who can actually
relate to the lived experience with and without PF
…”
“You see our symptoms are basically an
ongoing internal struggle to breathe freely …
and it’s invisible to all, including family, friends
and the general community.”
“I talked with a 60 something grandmother, who really enjoyed days looking after
grandkids, but as disease progressed she found sometimes she needed to reduce
the time a bit. You won’t believe that her daughter in law suggested she would just
bring them around less, ‘you’re always tired but you look really well’, so I won’t
bother you as much. Shattering to the poor woman obviously, but again
demonstrates the absolute lack of understanding of this debilitating disease. Looks
well, so can’t be too ill, except she’s struggling to breathe and is on a journey
with an inevitable end.”
Source: Bill van Nierop, https://www.facebook.com/kayakforlungs 28 September 2023
https://www.lonagkayakforlungs.com.au/
8
The need: better outcomes for Idiopathic Pulmonary Fibrosis (IPF) and
other fibrotic diseases
45% of developed world deaths have
72,000
>490,000
worldwide
78,000
a chronic fibrosis component
14,000
Europe
USA
Japan
159,000
6,000
China
Australia
of sufferers
die within 3 – 5
years
following
diagnosis
Slow, but do not halt progression.
Serious side effects limit compliance,
tolerability
Every organ vulnerable:
§ Lung (US$4b)
§ Kidney (US$10b)
§ Eye (US$15b)
§ Cancer (US$1b each)3
$5.1b
$4.3b
>100,000 pa
New drivers of incidence
§ “Long COVID”1
§ Re-emergence of silicosis
Estimates 2029
Source: GlobalData,2 company
financial reports, AdAlta analysis
PM George, et al, “Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy”, Lancet published online May 15, 2020.
GlobalData, Idiopathic Pulmonary Fibrosis: Competitive Landscape, April 2023
3 GlobaData, disease analysis reports
1
2
9
The value: Pharma companies are actively licensing IPF assets for
significant value
Upfront payment to
licensor
Contingent milestones
Clinical Phase at
transaction
Feb 23
Acquisition#
US$294m
N/A
2
Jan 23
China only license
US$76m^
US$336m
2
Aug-22
License
US$80m
US$620m
2
Apr-20
Acquisition*
US$45m
Not disclosed
2
Nov-19
License
US$390m
US$1,000m
2
Nov-21
Acquisition#
US$254m
N/A
2 (Ready)
Nov-20
License
€25m
€320m
2 (Ready)
Sep-21
License
US$152m
US$602m
2 (Ready)
Feb-21
License
Not disclosed
US$517.5m
1
Jul-19
License
€45m
€1,100m
1
Oct-22
Acquisition
US$255m
Not disclosed
Pre-clinical
(+ platform)
Licensor/target
Licensee/acquirer
Source: Company press releases; * Lead indication was diffuse cutaneous systemic sclerosis which usually evolves into IPF; # Did not complete; ^ Includes development milestones
AD-214 almost
Phase II ready
Transaction
Date
10
CXCR4 is an established GPCR target in fibrotic diseases
CXCR4 is a critical player in many fibrotic indications including lung, kidney,
heart, eye, skin
Immunohistochemical analysis of lung IPF
tissue showed expression of CXCR4 in
human lung tissue from IPF and ILD patients
with little staining in lung tissue from agematched non-disease controls1
HC
MP
FF
Normal
IPF – Idiopathic Pulmonary Fibrosis;
ILD – Interstitial Lung Disease;
HC – honeycomb cysts;
MP – mucus plugs,
FF – fibroblastic foci
1. Griffiths et al 2018; Jaffar et al 2020
2. Prasse et al 2017
3. Chen et al 2014
IPF patient
CXCR4 imaging demonstrates strong CXCR4 expression
correlated with areas of honeycombing in IPF
Changes in CXCR4 expression may be predictive of
response to pirfenidone and may have a role in
monitoring IPF disease progression2
Figure 2. Baseline serial CXCR4 PET/CT scans of 2 patients with
IPF
Real-time PCR for CXCR4 mRNA in kidney biopsies from
patients with secondary FSGS and from non-disease live
kidney donors (Control)3
AD-114 was selected as the lead candidate because of its optimal
antifibrotic properties
CXCR4 i-bodies demonstrate differential pharmacology, allowing optimization of target interaction
1.
Fletcher et al 2021 (unpublished)
AD-114
AD-272
AD-523
Affinity to CXCR4
(KD/nM)
4.2
1.8
9.2
Inhibition of β-arrestin
(IC50/µM)
1.18
1.38
2.94
Inhibition of cAMP
(IC50/nM)
99
300
225
Inhibition of HIV entry
(IC50/nM)
131
838
349
Attenuation of laser
induced eye leakage
and fibrosis1
YES
N/A
NO
12
Drug candidate AD-214 is a dual AD-114 i-body-Fc fusion protein with
optimized CXCR4 affinity and half-life
AD-214 CXCR4 antagonist
§ AD-114 i-body® within AD-214 is highly
specific to the CXCR4 ligand binding
pocket
i-body® Fc fusion protein
(~75kDa)
§ Selected for impact on anti-fibrotic
signaling over other CXCR4 functions
Therapeutic candidate
§ Dimer enhances avidity
§ Combining the anti-CXCR4 i-body® and the
Fc-domain of human IgG1 increases half life
§ Effector functions removed to prevent cell
killing
§ This structure also improves
manufacturability
13
In vitro and ex vivo studies support proposed multiple modes of action
A
B
C
A. Inhibiting inflammatory cell and fibrocyte
recruitment into the damaged tissue
White cell migration studies
% inhibition of migration
EXAMPLES
150
B. Inhibiting epithelial cell proliferation,
secretion of pro-fibrotic factors and EMT
C. Inhibiting fibroblast migration, differentiation
and ECM deposition during tissue remodelling
Airway basal cell proliferation
Precision cut lung slice collagen
AD-214
21H5-Fc
100
50
0
20 40 60 80 100
CXCR4 RO (%)
Schematic adapted from Wynn, 2011; AdAlta data
14
AD-214 efficacy validated in mouse model of IPF; suggestive of
minimum effective dose
Normal mouse lung tissue
IPF mouse lung tissue
21 days after bleomycin
IPF mouse lung tissue +
AD-214
21 days after bleomycin and AD214 at 10mg/kg every 4 days from
day 8
Results supportive of efficacy at human doses lower than 1
mg/kg if dosed sufficiently frequently
Murigenics_20210208. (# Statistical significance assessed using ANOVA and post-hoc Dunnett’s test; ns (not significant) = p >0.05, * = p<0.05, ** = p < 0.01 relative to 21-day bleomycin vehicle; negative control is an i-body® that
does not bind specifically to CXCR4; error bars are standard error of the mean).
1
15
NHP toxicology studies support AD-214 CXCR4 engagement; Phase I
dose selection
Pharmacokinetics
§ Average elimination half-life 22-29 h
§
AD-214 available for >3 days
Pharmacodynamics
§ >60% occupancy of the CXCR4 receptor (RO) on T cells for 72 h at
>30 mg/kg
§ High receptor binding for >3 days
Supportive of human therapeutic dose window including 10 mg/kg intravenously, weekly or every second week
ITR Laboratories 20210201_AD-214 28-Day TK study ; mean +/- SD of male and female subjects
16
Intravenous AD-214 Phase I healthy volunteer study confirms robust
safety profile1
AD-214 exposure (AUC), Cmax, Tmax increase in a dose proportional manner
Elimination half-life (t1/2) 39 h at 20 mg/kg
✓ AD-214 well tolerated in both single and multiple dose arms
✓ No immune response concerns observed
§ Phase I studied single doses to 20 mg/kg, multiple doses to 10 mg/kg
(10 mg/kg extension completes Q1 2024)
§ No clinically significant, consistent cytokine release
§ No dose limited adverse events
§ No serious adverse events
§ No concerning clinical lab results
1
§ No clinical symptoms related to immune response observed
§ Antidrug antibodies:
§ Detected in some healthy volunteers at 5 mg/kg AD-214.
§ Predominantly low titre, no evidence of tolerance or antibody induced
drug clearance.
§ Interim results at 10 mg/kg consistent or better than these findings
Compiled from Tables and Listings of study NCT04415671 data collected and monitored by independent CRO 2Data from 5mg/kg single and multiple dose cohorts
17
Transient increases in blood biomarkers demonstrate consistent
engagement of the target receptor, CXCR4
5 mg/kg data shown; 10 mg/kg interim data comparable
1
Compiled from Tables and Listings of study NCT04415671 data collected and monitored by independent CRO 2Data from 5mg/kg single and multiple dose cohorts
18
Phase 1 clinical study supports sustained AD-214 CXCR4 engagement
Understanding receptor occupancy is critical to inform dosing
§
White blood cells naturally express CXCR4, providing accessible surrogate for AD-214 target engagement
§
Sustained high levels of CXCR4 receptor occupancy (RO) by AD-214 on T cells observed even at very low circulating
concentrations of AD-214: >60% RO at 21 days after 20 mg/kg infusion
If replicated on CXCR4 receptors cell involved in fibrosis (including immune cells), results support extended dosing
intervals of ~2 weeks despite relatively rapid clearance from circulation
Figure created from data in Clinical Study Report: Protocol ID: ADA-AD-214-1A : Version 1 Dated 07 October 2022
19
Open question: what levels of receptor occupancy are needed for efficacy?
A. AD-214 has demonstrated efficacy in multiple animal models of fibrotic disease
B. In humans, AD-214 was able to maintain more than 60% receptor occupancy (blocking) for up to three weeks after IV infusion, depending on dose
C. Is this sufficient to achieve efficacy for target IV product profile (two weeks between doses)? Is a next generation SC product profile possible?
D. YES – new data shows that AD-214 does not require 100% receptor occupancy to meaningfully inhibit a model fibrotic process: efficacy of two weekly IV
dosing regimens is plausible AND weekly or daily SC dosing regimens appear possible
Source: ASX release 7 July 2023
20
Clinically viable, two weekly IV and weekly SC dosing regimens can
maintain target receptor occupancy for efficacy
1.
Ex vivo cell migration is a model fibrotic process and inhibition of migration is a model of efficacy
§ Maximum efficacy at >80% inhibition of migration (green). Meaningful efficacy at >50% inhibition (yellow)
2.
Less than full receptor occupancy (CXCR4 RO) is required for efficacy (meaningful inhibition of cell migration)
§ 60-85% receptor occupancy is sufficient for maximum inhibition of cell migration
§ Meaningful inhibition at receptor occupancy as low as 10-40%
3.
Maintaining efficacious receptor occupancy levels is the objective of dose selection
§ Efficacious receptor occupancy can be maintained for at least two weeks after an IV infusion and one potentially week after SC injection
in humans, a clinically viable dosing regimen2
Donor 1
AD-214
21H5-Fc
10-40% RO for
meaningful inhibition1
80
60
40
20
0
0
1.
2.
Target 50+% inhibition for of cell
migration for meaningful
efficacy
Target 80+% inhibition of cell
migration for maximum efficacy
80
60
LLOQ
40
20
0
20 40 60 80 100
0
% Inhibition of migration
1
5 mg/kg
10 mg/kg
20 mg/kg
100
CXCR4 RO (%)
2
CXCR4 RO (%)
100
60-80% RO for maximal
inhibition1
Phase I
1
2
3
4
Time since end of infusion (weeks)
3
Can be readily achieved for 2-3
weeks following a single IV infusion2
AdAlta studies correlated AD-214 concentration with level of CXCR4 receptor occupancy and level of inhibition of SDF-1a induced migration ex vivo on human T cells. Ranges are average of results from three healthy donors, only one
donor shown
Clinical Study Report: Protocol ID: ADA-AD-214-1A : Version 1 Dated 07 October 2022
21
PK models suggest two weekly IV and potentially weekly SC dosing
regimens achieve target receptor occupancy
A. Dosing every two weeks
10 mg/kg
B. Dosing every week
1 mg/kg
3 mg/kg
Potential SC dose
to introduce at
Phase III or
lifecycle
management
Target IV dose for
Phase II
Days
IV administration
SC administration
Days
Maximal inhibition of fibrotic process
Meaningful inhibition of fibrotic process
Simulated CXCR4 receptor occupancy following IV (red) and SC (blue) administration of AD-214 doses.
Shading represents receptor occupancy (RO) required for maximal (green) and meaningful (yellow, more than 50%) inhibition of a model
fibrotic process in ex vivo experiments.
Panel A: 10 mg/kg AD-214 administered every two weeks.
Panel B: 1 mg/kg (left) and 3 mg/kg (right) AD-214 administered every week.
AdAlta analysis based on PK/PD model developed by LYO-X
22
Phase I extension study validates model and safety of target
Phase II dose
Receptor occupancy (RO) in line with model predictions for efficacy of 10 mg/kg infusion every two weeks
Predicted RO
§
§
§
§
>80% at one week after infusion
>60% at 10-11 days after infusion
>30% at 14 days after infusion
Consistent profile across multiple doses
Observed RO (mean)
ü
§
ü
ü
>90% at one week after infusion
Not measured at 10-11 days after infusion
>30% at 14 days after infusion
Consistent profile across multiple doses
Tolerability: safety of target Phase II dose supported
5 mg/kg multiple (3) doses
§
§
§
§
§
No dose limiting toxicity
No serious adverse events (all AE’s mild or moderate)
Infusion related reactions in 3/8 participants; 2 dose
interruptions
Low level antidrug antibodies in 4/6 participants at 4 weeks;
no impact on PK/PD
Low level antidrug antibodies in 4/6 participants at 19 weeks
10 mg/kg multiple (3) doses
ü
ü
ü
ü
§
No dose limiting toxicity
No moderate adverse events (lower frequency mild AE’s)
Infusion related reactions in 1/8 participants; 0 dose
interruptions
Very low level antidrug antibodies in 2/6 participants; no
impact on PK/PD
PK/PD effect of antidrug antibodies at 16 weeks – TBD*
have received a 4th dose at 16 weeks (12 weeks after 3rd dose) to evaluate effect of immune response on pharmacokinetics (PK) and pharmacodynamics (PD) as measured by receptor occupancy (RO); results and full
analysis Q1 2024
23
AD-214 is a first in class CXCR4 antagonist designed specifically for
fibrotic disease, ready to move into Phase II
Product Profile: AD-214
Disease Area
Product development strategy
Fibrosis
Molecule class
Protein therapeutic (i-body®-Fc-fusion)
Target intravenous (IV)
product profile
Potential subcutaneous (SC)
product profile
Mode of action
First-in-class CXCR4 antagonist
IV administration in clinic
Patient self administration at
home (like diabetes, arthritis)
Indications
Idiopathic Pulmonary Fibrosis and Interstitial Lung
Disease (with kidney, eye and cancer indication extension
potential)
Two weeks minimum between
infusions: meets minimum
product criteria for clinical
adoption
Route of
administration
Target: Intravenous (IV)
Next generation: Subcutaneous (SC), inhaled
Fastest, cheapest to clinical
proof of concept
Enhanced market share,
reduced COGS
Clinical stage of
development
Phase I complete; extension study under way
Preparations for Phase II advancing
Progress to Phase II
Develop formulation, progress to
Phase II
Regulatory
Orphan Drug Designation (US FDA)
10-12 years market exclusivity (US and EU)
IP
Composition of matter 2036 (granted)
Method of treatment/dosing 2043 (pending)
Choice of formulation to take
through to Phase III
Manufacturing
cGMP manufacturing at KBI Biopharmaceuticals, USA
Based on relative success of each
development
Weekly or daily injections:
maximum convenience,
minimum costs
24
A modern targeting system for next generation drugs
For more information please contact:
Tim Oldham
CEO & Managing Director
+61 403 446 665
t.oldham@adalta.com.au
www.adalta.com.au
25
Share your feedback
Discover